Pharmaceutical companies carry out safety and environmental self-inspection
Release time:
2020-08-14
Pharmaceutical Company Launching Safety and Environmental Protection Self-inspection
News 5# July 22 - 25 and 6 5 , the Production Technology Department of Pharmaceutical Company took the lead in organizing inspection teams to conduct two safety and environmental protection self-inspections on Jinxi Pharmaceutical Factory and Qiubin Pharmaceutical Factory respectively in two stages.
As a listed company that meets the safety level 3 standardization standards and has passed the environmental ISO14001 certification, self-inspection in daily work determines the dynamic relationship between safe and environmentally friendly operation and standards. Therefore, in the annual plan of pharmaceutical company 2018 , referring to the inspection method of GMP , the concept of self-inspection was put forward for the first time, and the self-inspection plan was prepared in 4 . The basis of self-inspection shall be subject to laws and regulations, evidence collection and evaluation standards and the system of pharmaceutical companies. For the self-inspection from
5 22 to 25 , the inspectors conducted all-round inspection on the site and document records in groups, focusing on the implementation of laws and regulations list and compliance evaluation, factory safety production management system, risk identification and evaluation, quality / environmental management manual, environmental management procedures, etc, safety training records and "hazardous waste entrusted disposal agreement", "hazardous waste business license", "hazardous waste account", "emergency plan for environmental emergencies" and other contents. 6 August 5 self-inspection, the inspectors re-checked the maintenance of the relevant facilities of the sewage treatment system of Jinxi Plant, the implementation of the organic solvent tail gas absorption system in each workshop, the safety production system of the team and the relevant records, focusing on the investigation of the organic solvent that has failed in the inventory of the development department; The actual operation process of bulk management and sub-packaging of anhydrous ethanol in the storage tank loading and unloading area was checked, the discharge of rainwater outlets and the implementation of the approval authority for hazardous operations, and the self-assessment of special equipment.
Jinxi Factory and Qiubin Factory added a variety of records and facilities according to the requirements in the process of obtaining evidence, which made up for the lack of procedures in normal work. For example, according to the requirements of three-level standardization, they established "Emergency Rescue Equipment Account" and "Fire Fighting Facilities and Equipment Inspection and Maintenance Records" to ensure the normal use of fire fighting facilities. In the process of applying for the National Pollution Discharge Permit of Jinxi Factory, the entire environmental impact was re-checked and confirmed to ensure that the sewage discharge meets national requirements.
In the continuous inspection and rectification, the pharmaceutical company has made obvious improvements in safety and environmental protection. Through the inspection of 4 days, some problems were found, and the enterprise saw the distance from the standard. In the general environment, the pressure of safety and environmental protection is great, forcing enterprises to keep up with the situation only by continuous improvement and continuous improvement. Self-inspection as a way of inspection, as a powerful means of promotion, pharmaceutical companies will continue to strengthen rolling implementation, so as to promote the good development of safety and environmental protection of pharmaceutical companies. (Li Taohong)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page